ライフサイエンスコーパス: radiopharmaceutical

1 amycin as a phosphatidylethanolamine-binding radiopharmaceutical.

2 c focus is obtaining a timely injection of a radiopharmaceutical.

3 ired HCV infection from a blood-contaminated radiopharmaceutical.

4 d dose to all organs from this beta-emitting radiopharmaceutical.

5 ne, to form (99m)Tc(CO)(3)(LAN), a new renal radiopharmaceutical.

6 synthesis of the corresponding (111)In(III) radiopharmaceutical.

7 alanine ((18)F-FDOPA) is another interesting radiopharmaceutical.

8 h, 2 h, and 4 h after administration of the radiopharmaceutical.

9 ly half that of patients injected with other radiopharmaceuticals.

10 irradiation dose delivered to BM by injected radiopharmaceuticals.

11 predict the response of cell populations to radiopharmaceuticals.

12 omparable to that of other commonly used PET radiopharmaceuticals.

13 y being used to synthesize positron-emitting radiopharmaceuticals.

14 for evaluation of using them as PET imaging radiopharmaceuticals.

15 latory and payment considerations of new PET radiopharmaceuticals.

16 ntially when labeled with (131)I therapeutic radiopharmaceuticals.

17 ker research and discovery and validation of radiopharmaceuticals.

18 ocedures in the daily preparation of (99m)Tc radiopharmaceuticals.

19 ure syringe-and-vial radiolabeling of (68)Ga radiopharmaceuticals.

20 sing patient normal-organ kinetics for the 2 radiopharmaceuticals.

21 t impact on the synthesis and development of radiopharmaceuticals.

22 ive doses (MTBEDs) arising from the combined radiopharmaceuticals.

23 ium are unique compared with previously used radiopharmaceuticals.

24 find any particular concern about the use of radiopharmaceuticals.

25 Most reports (96.8%) were for diagnostic radiopharmaceuticals.

26 for the rapid, high-throughput screening of radiopharmaceuticals.

27 iologic effects associated with administered radiopharmaceuticals.

28 ncertainty in internal dose calculations for radiopharmaceuticals.

29 aration of clinical doses of (211)At-labeled radiopharmaceuticals.

30 echnique to prevent contamination of sterile radiopharmaceuticals.

31 okinetics and biodistribution of 90Y-labeled radiopharmaceuticals.

32 vels of SAB and possibly other 211At-labeled radiopharmaceuticals.

33 Drug Administration (FDA) reviews diagnostic radiopharmaceuticals.

34 ncertainty of the internal doses of 7 common radiopharmaceuticals.

35 uncertainty was developed and applied for 7 radiopharmaceuticals.

36 of absorbed doses and effective doses for 7 radiopharmaceuticals.

37 less successful when applied to evaluate new radiopharmaceuticals.

38 etic strategy for synthesis of (18)F-labeled radiopharmaceuticals.

39 r images, and use of pseudoplanar images and radiopharmaceuticals.

40 s been used to label various new therapeutic radiopharmaceuticals.

41 f 99mTc is a promising route to supply 99mTc radiopharmaceuticals.

42 which leads to a rapid preparation of (68)Ga radiopharmaceuticals (12-16 min).

43 Our group has developed a new radiopharmaceutical, (123)I - N-(2-diethylaminoethyl)-2-

44 GBq; maximum, 6.60 GBq) of the beta-emitting radiopharmaceutical (131)I-BA52.

45 those results to targeting of a therapeutic radiopharmaceutical [(131)I]FIAU to slow or stop tumor g

46 odonium(III) ylide precursor, to prepare the radiopharmaceutical (18)F-3-fluoro-5-[(pyridin-3-yl)ethy

47 vitro and in vivo uptake of pyrimidine-based radiopharmaceuticals ((18)F-FEAU) comparable to that of

48 the safety and effectiveness of a novel PET radiopharmaceutical, (18)F-3-fluoro-5-[(pyridin-3-yl)eth

49 Two commonly available radiopharmaceuticals-(18)F-FDG and (18)F-NaF-have been u

50 in the laboratory with the positron-emitting radiopharmaceutical 18FDG.

51 only (131)I-tositumomab, and 24.9% used both radiopharmaceuticals; 37.9% did not treat NHL with radio

52 This article describes the evaluation of the radiopharmaceutical (64)Cu-CB-TE2A-c(RGDyK) ((64)Cu-RGD)

53 The PET radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT is an attracti

54 o determine the dissociation constant of the radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT using AR42J ra

55 arget, for which purpose we designed the PET radiopharmaceutical (68)Ga-aquibeprin.

56 A new radiopharmaceutical, (68)Ga-labeled tris(hydroxypyridino

57 the pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)(3)-nitrilotriacetic acid

58 The pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)3-nitrilotriacetic acid (

59 luate the MTD, we adjusted the dosage of the radiopharmaceutical according to body surface area (BSA)

60 le detector simulating half the administered radiopharmaceutical activity.

61 e rapid SPECT acquisitions or a reduction in radiopharmaceutical activity.

62 ne examinations, including the minimum total radiopharmaceutical administered dose per examination, t

63 unity should develop pediatric standards for radiopharmaceutical administered doses and reduce radiat

64 th imaging initiated approximately 1 h after radiopharmaceutical administration.

65 1,024,177 radiopharmaceutical administrations were monitored: 207,

66 ear Medicine Society (BNMS) online database (Radiopharmaceutical Adverse Events and Product Defects)

67 the study period, there were 204 reports of radiopharmaceutical adverse reactions, of which 13 were

68 Members of the radiopharmaceutical advisory committee should decide on

69 r Medicine should choose the membership of a radiopharmaceutical advisory committee, and the FDA shou

70 The incidence of radiopharmaceutical AEs was 2.1/10(5) administrations, w

71 The choice of radiopharmaceutical agent for various studies is crucial

72 GD peptide (PEG3-E[c{RGDyk}]2) is a safe PET radiopharmaceutical agent.

73 in designing treatment plans for therapeutic radiopharmaceuticals, an applet software application cal

74 or because a causal relationship between the radiopharmaceutical and the adverse reaction could not b

75 signed to automate the extraction of data on radiopharmaceuticals and administered activities from nu

76 the prevalence of, and association between, radiopharmaceuticals and adverse reactions.

77 This article reviews radiation dosimetry for radiopharmaceuticals and also CT given the recent prolif

78 potential in clinics likely will require new radiopharmaceuticals and applications other than whole-b

79 hat CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with cas

80 Uptake of radiopharmaceuticals and chemotherapeutic drugs is nonun

81 timal imaging approach using 4 different PET radiopharmaceuticals and CT/MRI in these patients.

82 al perspective in the realm of bone-targeted radiopharmaceuticals and discuss how these agents compar

83 ng decisions on Medicare coverage of new PET radiopharmaceuticals and imaging procedures that are cur

84 produce new standardized dose estimates for radiopharmaceuticals and other applications.

85 uptake curves can be used to rapidly screen radiopharmaceuticals and other cytotoxic agents to formu

86 Research and discovery of novel radiopharmaceuticals and targets thereof generally invol

87 The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the (18)F(

88 reparation of clinical-level (211)At-labeled radiopharmaceuticals and when the labeling chemistry is

89 s (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive phar

90 ss of (99m)Tc(III)-based compounds useful in radiopharmaceutical applications.

91 and updated as models are changed and as new radiopharmaceuticals are added.

92 d radiosynthesis protocols for (18)F-labeled radiopharmaceuticals are an indispensable but often over

93 ugs such as bisphosphonates and bone-seeking radiopharmaceuticals are being applied in novel ways in

94 s have been established, and therefore these radiopharmaceuticals are being investigated for clinical

95 Bone-targeting radiopharmaceuticals are beneficial in the management of

96 nonradioactive drugs and several diagnostic radiopharmaceuticals are considered.

97 ATOC and (68)Ga-PSMA-HBED-CC investigational radiopharmaceuticals are currently being studied clinica

98 l trials of palliative radiation therapy and radiopharmaceuticals are emphasized, and new concepts in

99 It is widely recognized that radiopharmaceuticals are generally distributed nonunifor

100 18)F-labelled building blocks, compounds and radiopharmaceuticals are synthesized.

101 d monoclonal antibodies either alone or with radiopharmaceuticals, are being used to seek and destroy

102 As a first step toward validating this radiopharmaceutical as an imaging biomarker for AD, we m

103 arbazone) (copper-ATSM), a hypoxia-targeting radiopharmaceutical, assessed by PET has been found to c

104 Avid Radiopharmaceuticals, Banner Alzheimer's Foundation, Nom

105 significant doses of scVEGF/(177)Lu, a novel radiopharmaceutical based on a recombinant single-chain

106 (11)C-Carbonyl radiopharmaceuticals based on labeled carboxylic acids,

107 A compendium of about 100 radiopharmaceuticals, based on the OLINDA/EXM version 2.

108 production of clinically relevant levels of radiopharmaceutical because of radiolytic effects.

109 ally showed promise as an infection-specific radiopharmaceutical, but subsequent investigations were

110 yer chromatography (iTLC), HPLC and pH), the radiopharmaceutical can be directly administered to pati

111 Conclusion (18)F FSPG is a PET radiopharmaceutical characterized by rapid clearance fro

112 ate tracer selection, the impact of improved radiopharmaceutical chemistry in radiotracer development

113 The clinical role and safety profile of radiopharmaceuticals combined with chemotherapy in prost

114 The number of radiopharmaceuticals containing copper radionuclides for

115 lay a pivotal role in (18) F-fluorination of radiopharmaceuticals containing non-activated arenes.

116 sterile, nonsterile, or potential hazardous radiopharmaceuticals, coupled with the limited space of

117 is believed to play a key role in steroidal radiopharmaceutical delivery to target tissues in humans

118 xy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical depicting tumor cell proliferation w

119 is it time to reevaluate our strategies for radiopharmaceutical design and use?

120 ential of the method for applications in PET radiopharmaceutical design.

121 excretion into the bladder similar to other radiopharmaceuticals developed for gamma-camera renograp

122 l imaging agents and support continued renal radiopharmaceutical development based on the (99m)Tc-tri

123 fluoromethylarenes from [(18) F]fluoride for radiopharmaceutical discovery is reported.

124 advantages and limitations of the available radiopharmaceuticals, discusses quality control elements

125 Longitudinal imaging with different radiopharmaceuticals displays various characteristics in

126 Currently, chelating agents used in (68)Ga radiopharmaceuticals do not meet this ideal.

127 t the stress-only group received a 61% lower radiopharmaceutical dosage.

128 The combined uncertainties in most radiopharmaceutical dose estimates will be typically at

129 versally applied standards for administering radiopharmaceutical doses in children do not presently e

130 ion, sedation, local and general anesthesia, radiopharmaceutical doses, radiation risk, and dose redu

131 Hence, pediatric radiopharmaceutical dosimetry varies considerably from i

132 Administration (FDA) approval of diagnostic radiopharmaceuticals (DRs) are described in laws that br

133 be a new positron emission tomographic (PET) radiopharmaceutical, fluorine 18 ((18)F) 2-fl uoropropio

134 Therefore, a radiolabeled iNOS radiopharmaceutical for assessing iNOS protein concentra

135 udy was to validate (18)F-FDS as a potential radiopharmaceutical for imaging bacterial infection long

136 o may allow for clinical translation of this radiopharmaceutical for imaging tumor angiogenesis and g

137 suggests that (68)Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patie

138 ptide ((18)F-FtRGD) to determine the optimal radiopharmaceutical for measuring the early treatment re

139 Rubidium-ARMI ((82)Rb as an Alternative Radiopharmaceutical for Myocardial Imaging) is a multice

140 tion the conjugate as a potential diagnostic radiopharmaceutical for patients suffering from small-ce

141 istribution investigation of the use of this radiopharmaceutical for possible future use in the diagn

142 no acid infusion was coadministered with the radiopharmaceutical for renal protection.

143 arrant further investigation of 18F-PFH as a radiopharmaceutical for the assessment of renal function

144 n vitro and in vivo evaluation of this novel radiopharmaceutical for the detection of IL2 receptor-po

145 dopa ((18)F-FDOPA) has proven to be a useful radiopharmaceutical for the evaluation of presynaptic do

146 ctive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin rece

147 e-sst2-AN T (64Cu-CB-TE2A-sst2-ANT) as a PET radiopharmaceutical for the in vivo imaging of SSTR2-pos

148 the most frequently used radioisotope in PET radiopharmaceuticals for both clinical and preclinical r

149 inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (

150 ding hybrid imaging, the introduction of new radiopharmaceuticals for diagnosis and therapy, and the

151 ven too much importance when one is choosing radiopharmaceuticals for general clinical use.

152 profile of PF-367 is ideal for discovery of radiopharmaceuticals for GSK-3 in the central nervous sy

153 is a well-established target for developing radiopharmaceuticals for imaging and therapy of prostate

154 eloping a new class of tumor-specific (64)Cu radiopharmaceuticals for imaging neuroblastoma and melan

155 is the most commonly used isotope to prepare radiopharmaceuticals for molecular imaging by positron e

156 stigation of (18)F-labeled rhodamines as PET radiopharmaceuticals for myocardial perfusion imaging.

157 n and high labeling yields of (68)Ga-labeled radiopharmaceuticals for routine medical application.

158 g ligands such as RPS-027 as next-generation radiopharmaceuticals for targeted alpha-therapy using (2

159 lly introduced as a new class of theranostic radiopharmaceuticals for the treatment of prostate cance

160 However, using folate-based radiopharmaceuticals for therapy has long been regarded

161 Final estimates of absorbed dose for radiopharmaceuticals, for example, were only slightly di

162 f (EH)3 on the biodistribution of 2 peptidic radiopharmaceuticals, Glu-urea-Lys(Ahx)-HBED-CC and TATE

163 e of (131)I-o-iodohippuran ((131)I-OIH), the radiopharmaceutical gold standard for the measurement of

164 Cholescintigraphy with (99m)Tc-hepatobiliary radiopharmaceuticals has been an important, clinically u

165 Systemic therapy using bone-seeking radiopharmaceuticals has clear advantages for the treatm

166 Dose coefficients of radiopharmaceuticals have been published by the Internat

167 urally diverse and novel clinically relevant radiopharmaceuticals have been synthesized with both hig

168 64Cu radiopharmaceuticals have shown tumor growth inhibition

169 We report on a radiopharmaceutical imaging platform designed to capture

170 utic efficacy, 2 groups of mice received the radiopharmaceutical in a median dose of either 165 MBq (

171 a significant 3-fold higher retention of the radiopharmaceutical in clorgyline-treated animals.

172 of a (99m)Tc-tricarbonyl complex as a renal radiopharmaceutical in humans demonstrate that (99m)Tc(C

173 ET imaging showed rapid accumulation of this radiopharmaceutical in the atherosclerotic abdominal aor

174 There were no observed adverse events to the radiopharmaceutical in the immediate or delayed time fra

175 ecular diagnostic markers, and validation of radiopharmaceuticals in both rodent and human cell lines

176 d radionuclides or increased localization of radiopharmaceuticals in radiosensitive kidney subregions

177 om other clinical PET tracers and diagnostic radiopharmaceuticals in routine clinical use.

178 Our goal is to put these radiopharmaceuticals in the context of mCRPC biology and

179 Three studies compared the 2 radiopharmaceuticals in the same patient, finding (68)Ga

180 This applet models the distribution of radiopharmaceuticals in tissues, calculates the distribu

181 s expended on new pharmaceuticals, including radiopharmaceuticals, in order to identify the most prom

182 examination and administered activity of the radiopharmaceutical; in addition, it should be explained

183 18) F-difluoromethylarene drug analogues and radiopharmaceuticals including Claritin, fluoxetine (Pro

184 It has been imaged using several radiopharmaceuticals, including (18)F-FDG.

185 ng the Food and Drug Administration-approved radiopharmaceutical indium 111 octreotide.

186 xit after PET/CT imaging or just after SPECT radiopharmaceutical injection appears to be safe from a

187 t comparison to other imaging, and time from radiopharmaceutical injection to imaging.

188 ses, patients were asked to void proximal to radiopharmaceutical injection.

189 ents left the department earlier, just after radiopharmaceutical injection.

190 All patients received radiopharmaceutical injections drawn from a single pharm

191 integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy reg

192 y administered with a dose of a bone-seeking radiopharmaceutical is superior to chemotherapy alone.

193 tal critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system t

194 A history of the regulation of radiopharmaceuticals is presented.

195 A description of radiometal-based radiopharmaceuticals is provided, and several key design

196 nuclei from internalizing, receptor-targeted radiopharmaceuticals is related to chelate stability.

197 a (68)Ge/(68)Ga generator into a lyophilized radiopharmaceutical kit in 1 step without manipulation.

198 al anionic, cationic, and neutral technetium radiopharmaceutical kits.

199 rable to other previously reported RGD-based radiopharmaceuticals labeled with (68)Ga and (18)F.

200 use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitter

201 e the pharmacokinetic properties of peptidic radiopharmaceuticals, leading to reduced uptake in organ

202 These Pgp-directed properties of the radiopharmaceutical may also translate favorably to myoc

203 In addition, these radiopharmaceuticals may shed light on BAT physiology.

204 AC), of a diagnostic/therapeutic convergence radiopharmaceutical, namely (64)Cu-/(177)Lu-labeled anti

205 dely used in the testing and approval of new radiopharmaceuticals, necessitating murine phantom model

206 the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and

207 (18)F-FDG is the radiopharmaceutical of choice for spondylodiskitis.

208 gan doses from the administered activity and radiopharmaceutical of each examination were provided.

209 68)Ga-DOTATATE, and CT/MRI and should be the radiopharmaceuticals of choice in this rare group of pat

210 d batch-mode microfluidic devices to produce radiopharmaceuticals of sufficient quality and quantity

211 However, radiopharmaceuticals passing though the kidneys result i

212 Radiopharmaceutical pharmacokinetics are usually approxi

213 ied D-methionine as a probe with outstanding radiopharmaceutical potential.

214 ensures the removal of (68)Ge before (68)Ga-radiopharmaceutical preparation and high labeling yields

215 improved logistics for the delivery of (18)F radiopharmaceuticals, prior limitations to the routine u

216 f adapting these new reactions for automated radiopharmaceutical production has revealed limitations

217 Nuclear pharmacies prepare radiopharmaceutical products for use in common diagnosti

218 eparate study of PROSTVAC-VF combined with a radiopharmaceutical (Quadramet).

219 art 1 of this review addressed the available radiopharmaceuticals, quality control, and quantitative

220 ence of skeletal-related events, whereas the radiopharmaceutical radium-223 is shown to reduce the in

221 ((67)Ga) and generator-produced PET ((68)Ga) radiopharmaceutical recognized by MDR1 Pgp.

222 Beta-emitting radiopharmaceuticals reduce pain due to metastatic disea

223 The prevalence of adverse reactions to radiopharmaceuticals reported in the BNMS database remai

224 ce while optimizing the ratio of 2 different radiopharmaceuticals required to maximize tumor control.

225 Clinical investigation of these radiopharmaceuticals requires the production of high act

226 use of current human dosimetry models during radiopharmaceutical research.

227 s, which makes them excellent candidates for radiopharmaceutical research; hence their synthesis and

228 tion dose estimates for different diagnostic radiopharmaceuticals should be appreciated and considere

229 small differences in dose estimates between radiopharmaceuticals should not be given too much import

230 PSMA-specific radiopharmaceuticals should provide a novel molecular ta

231 In this way, requirements would be radiopharmaceutical-specific, and much information of qu

232 Several radiopharmaceuticals such as (18)F-FDG, (123)I-metaiodob

233 BC that are comparable to those of other PET radiopharmaceuticals such as (18)F-FDG.

234 ation may change with the development of new radiopharmaceuticals, such as prostate-specific membrane

235 These (99m)Tc-labeled radiopharmaceuticals targeting PSMA may provide a SPECT

236 essed in prostate cancer, and small-molecule radiopharmaceuticals targeting PSMA rapidly detect the l

237 ration in the development of (99m)Tc-labeled radiopharmaceuticals targeting PSMA.

238 near-infrared cyanine dye, to tilmanocept, a radiopharmaceutical that binds to a receptor specific to

239 (64)Cu-ATSM appears to be a safe radiopharmaceutical that can be used to obtain high-qual

240 (18)F FPPRGD2 is a safe PET radiopharmaceutical that has increased uptake in GBM les

241 We reasoned that a radiopharmaceutical that measures intratumoral changes i

242 o-)phenyl-imidazo[1,2-a]pyridine) is a novel radiopharmaceutical that selectively binds to Alzheimer'

243 We also briefly consider novel radiopharmaceuticals that are beginning to be used in th

244 future translation to patient studies using radiopharmaceuticals that are currently available for bo

245 however, is expected in the synthesis of PET radiopharmaceuticals that can be made only with low yiel

246 We presented a list of potential radiopharmaceuticals that can be used in detecting vario

247 ocedures for cancer therapy are administered radiopharmaceuticals that emit various types of radiatio

248 ining the optimal time to reinfuse PBSCs for radiopharmaceuticals that have much a higher activity co

249 range of substrates, facilitating access to radiopharmaceuticals that were challenging to synthesize

250 assessed all reports of adverse reactions to radiopharmaceuticals that were submitted to the British

251 able (68)Ga-DOTATOC (or other (68)Ga-labeled radiopharmaceuticals) that are suitable for routine appl

252 However, with lack of specific radiopharmaceuticals, their pharmacology is still incomp

253 important information on the response during radiopharmaceutical therapy (RPT).

254 a similar chelator/scaffold combination for radiopharmaceutical therapy based on the structure of 6.

255 Although the rationale for combination radiopharmaceutical therapy was described in the mid-199

256 PSMA-targeted radiopharmaceutical therapy with the Auger emitter (125)

257 Eligible patients were offered salvage radiopharmaceutical therapy with the novel NTR1 antagoni

258 Radiopharmaceutical therapy, traditionally limited to re

259 rational implementation of combined targeted radiopharmaceutical therapy.

260 on (177)Lu (lutetium) and its application in radiopharmaceutical therapy.

261 marrow doses, further supporting its use for radiopharmaceutical therapy.

262 efficiency can require larger amounts of the radiopharmaceutical to be administered, possibly leading

263 fluorodopamine (F-DA) is being used as a PET radiopharmaceutical to image adrenergic innervation and

264 , (123)I-iododexetimide may be an attractive radiopharmaceutical to image M1R.

265 able synthesizer, restricting access to this radiopharmaceutical to only a few PET centers.

266 roved alpha-emitter, (223)RaCl2 is the first radiopharmaceutical to show an increase in overall survi

267 process and assist in bringing new targeted radiopharmaceuticals to approval over the next few years

268 The reported administered doses of radiopharmaceuticals to children vary over a relatively

269 was unrealistic to expect trials of new PET radiopharmaceuticals to directly demonstrate a health be

270 udy was to use estrogen- and progestin-based radiopharmaceuticals to image ERalpha and PR in mouse ma

271 A rational approach for combination radiopharmaceutical treatment has been developed within

272 is considered a nontoxic, safe-to-administer radiopharmaceutical unlikely to cause adverse effects in

273 concentration ratios for several examples of radiopharmaceutical uptake and clearance.

274 Es) in PET can cause incorrect estimation of radiopharmaceutical uptake in small tumors.

275 ng and SPECT were used for quantification of radiopharmaceutical uptake in vivo; 4.7-T MR imaging was

276 n situ high-spatial-resolution validation of radiopharmaceutical uptake.

277 institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011.

278 2011, PET studies increased, and therapeutic radiopharmaceutical use and bone scintigraphy were uncha

279 We studied the changing patterns of radiopharmaceutical use and the incidence of adverse eve

280 PET radiopharmaceutical use increased from 17% to 26% of dia

281 al studies of new diagnostic and therapeutic radiopharmaceuticals use murine animal models for precli

282 1)I-metaiodobenzylguanidine ((131)I-MIBG), a radiopharmaceutical used for the therapy of neuroendocri

283 cal basis for the dose estimates for several radiopharmaceuticals used in nuclear cardiology is revie

284 Although iodinated radiopharmaceuticals usually contain a small quantity of

285 ts who received injections drawn from select radiopharmaceutical vials prepared on October 14-15, 200

286 The dissociation constant value for the radiopharmaceutical was determined to be 26 +/- 2.4 nM,

287 ed with (64)Cu-RGD to determine whether this radiopharmaceutical was sensitive enough to detect a res

288 , a high-affinity VLA-4 peptidomimetic-based radiopharmaceutical, was evaluated in alpha4 knock-out m

289 adverse effects in relation to safety of the radiopharmaceutical were observed.

290 Both radiopharmaceuticals were also compared in vivo through

291 st line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or sm

292 This radiopharmaceutical, which is based on an aminopolycarbo

293 erapy success, technical advances, and novel radiopharmaceuticals will all contribute to sustained gr

294 153 ((153)Sm) lexidronam is a bone-targeting radiopharmaceutical with a short physical half-life and

295 (18)F-PBR111 is a newly developed PET radiopharmaceutical with high affinity and selectivity f

296 these radioisotopes allow the preparation of radiopharmaceuticals with identical pharmacokinetics use

297 2) of an SnO2-based generator, affording the radiopharmaceuticals with specific activities greater th

298 a stable, low-molecular-weight PtdE-binding radiopharmaceutical, with favorable in vivo imaging prof

299 nce should generally dictate the choice of a radiopharmaceutical, with radiation dose being only a se

300 Extension of this methodology to other radiopharmaceuticals would yield the data required to ge